LIFE SAVING DRUGS PROGRAM EXPERT PANEL

18th MEETING: 28 June 2024

**AGENDA**

1. **Standing business**
	1. Welcome, apologies and Conflicts of Interest
	2. Update on actions from previous meetings
	3. Correspondence
	4. Report from the Secretariat
2. **24 month review of existing LSDP medicines**
	1. Avalglucosidase alfa (Nexviazyme®) – for the treatment of Pompe disease
3. **Other business**
	1. HTA Policy and Methods Review
	2. Expansion of the newborn bloodspot screening program: Implications for the LSDP

Note: There are no applications for new listings being discussed at this meeting.